The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status
Open Access
- 19 October 2017
- journal article
- research article
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 43 (5), 1755-1766
- https://doi.org/10.1159/000484062
Abstract
Background/Aims: Ovarian cancer is often diagnosed at later stages with poor prognosis. Recent studies have associated the expression of deubiquitylase USP7 with the survival of ovarian cancers. Being a cysteine protease, USP7 could become a target for pharmacological intervention. Therefore, in this study, we assessed the influence of its inhibitor P5091 on ovarian cancer cells. Methods: Ovarian cancer cells were treated with P5091, and cell proliferation was measured with MTT assay; cell morphology was inspected under a phase-contrast microscope; cell cycle and cell death were examined by flow cytometry. To gain mechanistic insights into its effects, immunoblotting was performed to detect USP7, HDM2, p53, p21, apoptosis and autophagy related proteins. Results: P5091 effectively suppressed the growth of ovarian cancer cells, caused cell cycle blockage, and induced necrosis and apoptosis with more severe phenotypes observed in HeyA8 cells with wild-type p53 than in OVCAR-8 cells with mutant p53. P5091 also prompted autophagy, with more efficient p62 degradation in HeyA8. Conclusion: P5091 shows efficacy in suppressing ovarian cancers harbouring wild-type and mutant p53. Its effects seemed to be enhanced by wild-type p53. The potency of this USP7 inhibitor also correlated with autophagy to some extent. Therefore, the pharmacological targeting of USP7 may serve as a potential therapeutic strategy and warrants further investigation. (C) 2017 The Author(s) Published by S. Karger AG, BaselKeywords
This publication has 37 references indexed in Scilit:
- Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2014
- Cancer statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- DEUBIQUITYLASES FROM GENES TO ORGANISMPhysiological Reviews, 2013
- Inhibitory Effect of Tumor Suppressor p53 on Proinflammatory Chemokine Expression in Ovarian Cancer Cells by Reducing Proteasomal Degradation of IκBPLOS ONE, 2012
- The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysisNucleic Acids Research, 2012
- A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib ResistanceCancer Cell, 2012
- The Multifaceted Roles of USP7: New Therapeutic OpportunitiesCell Biochemistry and Biophysics, 2011
- Emerging roles of deubiquitinases in cancer‐associated pathwaysIUBMB Life, 2010
- Breaking the chains: structure and function of the deubiquitinasesNature Reviews Molecular Cell Biology, 2009
- The multiple levels of regulation by p53 ubiquitinationCell Death & Differentiation, 2009